Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial
Why the study?
Does rivaroxaban prevent stroke or systemic embolism compared to dose-adjusted warfarin in East Asian patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation at moderate to high stroke risk from the ROCKET AF trial…
Comparison
Rivaroxaban vs Dose-adjusted warfarin
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Supports rivaroxaban use in East Asian NVAF patients; confirms consistent efficacy versus warfarin across populations.
Structured PICO
Does rivaroxaban prevent stroke or systemic embolism compared to dose-adjusted warfarin in East Asian patients with nonvalvular atrial fibrillation?
P
Population
Patients with nonvalvular atrial fibrillation at moderate to high stroke risk from the ROCKET AF trial, including 932 East Asian participants.
I
Intervention
Rivaroxaban (20 mg once daily; 15 mg once daily for creatinine clearance of 30-49 mL/min)
C
Comparator
Dose-adjusted warfarin
O
Outcome
Stroke or systemic embolismcomposite
Rivaroxaban demonstrates consistent efficacy and safety compared to warfarin for stroke prevention in East Asian patients with nonvalvular atrial fibrillation, supporting its use in this population.
Cite This Study
Wong et al. (2014) studied this question.